["(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN microRNA-17)))) (VP (VBZ improves) (NP (NP (NP (NN lung)) (CC and) (NP (NN heart))) (NN function)) (PP (IN in) (NP (JJ experimental) (JJ pulmonary) (NN hypertension))))) (. .)))", "(S1 (S (NP (NP (NN RATIONALE)) (: :) (S (NP (NP (NNS MicroRNAs)) (PRN (-LRB- -LRB-) (NP (NNS miRs)) (-RRB- -RRB-))) (VP (VBP control) (NP (NP (JJ various) (JJ cellular) (NNS processes)) (PP (IN in) (NP (NP (NN tissue) (NN homeostasis)) (CC and) (NP (NN disease))))) (PP (IN by) (S (VP (VBG regulating) (NP (NP (NN gene) (NN expression)) (PP (IN on) (NP (DT the) (JJ posttranscriptional) (NN level))))))))) (. .))))", "(S1 (S (S (ADVP (RB Recently)) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN miR-21)) (CC and) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NN miR-17-92) (NN cluster))))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN altered) (PP (IN in) (NP (NP (JJ experimental) (JJ pulmonary) (NN hypertension)) (PRN (-LRB- -LRB-) (NP (NN PH)) (-RRB- -RRB-))))))))))) (. .)))", "(S1 (S (NP (NP (NNS OBJECTIVES)) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NP (JJ therapeutic) (NN efficacy)) (CC and) (NP (JJ antiremodeling) (NN potential))) (PP (IN of) (NP (NN miR) (NNS inhibitors))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN PH))))))))) (. .))))", "(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (PRP We)) (ADVP (RB first)) (VP (VBD tested) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN miR) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNS antagomirs)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (ADVP (RB specifically)) (VP (VBN designed) (S (VP (TO to) (VP (VB block) (NP (NP (NP (NN miR-17)) (PRN (-LRB- -LRB-) (NP (NN A-17)) (-RRB- -RRB-))) (, ,) (NP (NP (NN miR-21)) (PRN (-LRB- -LRB-) (NP (NN A-21)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN miR-92a)) (PRN (-LRB- -LRB-) (NP (NN A-92a)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NP (JJ chronic) (JJ hypoxia-induced) (NN PH)) (PP (IN in) (NP (NNS mice)))) (CC and) (NP (NP (NN A-17)) (PP (IN in) (NP (NP (JJ monocrotaline-induced) (NN PH)) (PP (IN in) (NP (NNS rats)))))))))))))))))) (. .))))", "(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ biological) (NN function)) (PP (IN of) (NP (NN miR-17)))) (VP (VBD was) (VP (VBN analyzed) (PP (IN in) (NP (VBN cultured) (JJ pulmonary) (NN artery) (NN smooth) (NN muscle) (NNS cells)))))) (. .)))", "(S1 (S (NP (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (PP (IN In) (NP (DT the) (NN PH) (NN mouse) (NN model))) (, ,) (S (NP (NP (NN A-17)) (CC and) (NP (NN A-21))) (VP (VBD reduced) (NP (JJ right) (JJ ventricular) (JJ systolic) (NN pressure)))) (, ,) (CC and) (S (NP (DT all) (NNS antagomirs)) (VP (VBD decreased) (NP (JJ pulmonary) (JJ arterial) (NN muscularization))))) (. .))))", "(S1 (S (ADVP (RB However)) (, ,) (NP (JJ only) (NN A-17)) (VP (VP (VBD reduced) (NP (JJ hypoxia-induced) (JJ right) (NN ventricular) (NN hypertrophy))) (CC and) (VP (VBD improved) (NP (JJ pulmonary) (NN artery) (NN acceleration) (NN time)))) (. .)))", "(S1 (S (S (PP (IN In) (NP (DT the) (JJ monocrotaline-induced) (NN PH) (NN rat) (NN model))) (, ,) (NP (NN A-17) (NN treatment)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ right) (JJ ventricular) (JJ systolic) (NN pressure)) (CC and) (NP (JJ total) (JJ pulmonary) (JJ vascular) (NN resistance)) (NP (NN index))) (, ,) (NP (VBN increased) (JJ pulmonary) (NN artery) (NN acceleration) (NN time)) (, ,) (NP (VBN normalized) (JJ cardiac) (NN output)) (, ,) (CC and) (NP (VBN decreased) (JJ pulmonary) (JJ vascular) (NN remodeling))))) (. .)))", "(S1 (S (S (PP (IN Among) (NP (DT the) (VBN tested) (NN miR-17) (NNS targets))) (, ,) (NP (DT the) (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1A) (-LRB- -LRB-) (NN p21) (-RRB- -RRB-)) (VP (VBD was) (VP (VBN up-regulated) (PP (IN in) (NP (NP (NNS lungs)) (VP (VBG undergoing) (NP (NN A-17) (NN treatment)))))))) (. .)))", "(S1 (S (S (ADVP (RB Likewise)) (, ,) (PP (IN in) (NP (JJ human) (JJ pulmonary) (NN artery) (NN smooth) (NN muscle) (NNS cells))) (, ,) (NP (NN A-17)) (VP (VBD increased) (NP (NN p21)))) (. .)))", "(S1 (S (S (NP (NP (NN Overexpression)) (PP (IN of) (NP (NN miR-17)))) (ADVP (RB significantly)) (VP (VP (VBD reduced) (NP (NN p21) (NN expression))) (CC and) (VP (VBD increased) (NP (NP (NN proliferation)) (PP (IN of) (NP (NN smooth) (NN muscle) (NNS cells))))))) (. .)))", "(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN A-17)) (VP (VBZ improves) (NP (NP (NP (NN heart)) (CC and) (NP (NN lung))) (NN function)) (PP (IN in) (NP (JJ experimental) (NN PH))) (PP (IN by) (S (VP (VBG interfering) (PP (IN with) (NP (NN lung) (ADJP (ADJP (JJ vascular)) (CC and) (ADJP (JJ right))) (NN ventricular) (NN remodeling))))))))))) (. .))))", "(S1 (S (S (NP (DT The) (JJ beneficial) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN up-regulation)) (PP (IN of) (NP (NN p21))))))))) (. .)))", "(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN miR-17)))) (VP (MD may) (VP (VB represent) (NP (NP (DT a) (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN concept)) (S (VP (TO to) (VP (VB ameliorate) (NP (NP (NN disease) (NN state)) (PP (IN in) (NP (NN PH))))))))))) (. .)))"]